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ABSTRACT 
Background 
A possible relationship between mitochondrial haplogroups and psychiatric diseases (e.g. 
schizophrenia and bipolar disorder) has been postulated, but data regarding depression is still 
limited. We investigated whether any mitochondrial haplogroup carried a significant higher risk of 
depressive symptoms in a large prospective cohort of North American people included in the 
Osteoarthritis Initiative.     
Methods 
Cross sectional data was derived from the Osteoarthritis Initiative. The haplogroup was assigned 
through a combination of sequencing and PCR-RFLP techniques. All the mitochondrial 
haplogroups were named following this nomenclature: H, U, K, J, T, V, SuperHV, I, W, X or 
Others. Depression was ascertained through the 20-item Center for Epidemiologic Studies-
Depression (CES-D), with >16 indicating depressive symptoms.  
Results 
Overall, 3,601 Caucasian participants (55.9% women), mean age of 61.7±9.3 years were included. 
No difference was observed in mitochondrial haplogroups frequency among those with depressive 
symptoms (n=285, =7.9% of the baseline population) compared to participants with no depressive 
symptoms (N=3,316) (chi-square test=0.53). Using a logistic regression analysis, adjusted for eight 
potential confounders, with those having the haplogroup H as the reference group (the most 
common haplogroup), no significant mitochondrial haplogroup was associated with prevalent 
depressive symptoms. The same results were evident in secondary analysis in which we matched 
depressed and non-depressed participants for age and sex. 
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Limitations 
cross-sectional design; only CES-D for evaluating mood; participants not totally representative of 
general population.  
Conclusions 
We found no evidence of any relationship between specific mitochondrial haplogroups and 
depressive symptoms . Future longitudinal research is required to confirm/ refute these findings.   
 
Keywords: mitochondrial haplogroups; depression; osteoarthritis initiative.   
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INTRODUCTION 
The human mitochondrial genome is a circular set of 16,569 base pairs encoding 37 genes and 
finally 13 proteins, involved in processes relevant to cellular function and survival. (Wang and 
Brinton, 2016) Similarly to nuclear DNA mitochondrial DNA (mtDNA) undergoes frequent 
mutations.(Copeland and Longley, 2014; Wang and Brinton, 2016) Mismatch, usually due to a 
recombination or repair, can lead to single nucleotide polymorphisms (SNPs) and clusters of these 
specific SNPs in the mitochondrial genome define the mitochondrial haplogroups. The evolution of 
mtDNA occurs at a much faster pace compared to the average nuclear DNA, and thus mutations 
have accumulated sequentially, even if only along radiating maternal lineages. (Wallace and 
Chalkia, 2013) Therefore, it is hardly surprising that the biology of mitochondrial DNA may partly 
explain the genetic predisposition to certain medical conditions, probably in a similar way to the 
germline mutations of nuclear DNA.(Luchini et al., 2016; Mafficini et al., 2016) Recent studies 
have proposed that the different mitochondrial haplogroups might play a role in the development of 
several chronic disease states.(Mishmar et al., 2003; Picard et al., 2016; Wallace and Chalkia, 2013) 
Each of the mitochondrial haplogroups, in fact, is probably involved not only in mitochondria 
physiology, but also in cell metabolism. (Horan and Cooper, 2014; Wallace, 2015) Thus, organs at 
high consumption of energy (such as brain) are the main target of mitochondrial dysfunction.(Mink 
et al., 1981)  
 
From an epidemiological viewpoint, several psychiatric conditions, such as schizophrenia and mood 
disorders have a preferential transmission through the maternal line.(Kirk et al., 1999) Moreover, 
more recent studies reported that mood disorders are more frequent in maternal relatives of children 
with mitochondrial diseases, compared with their paternal relatives, or compared with maternal 
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relatives of the children with other metabolic diseases.(Grigoroiu-Serbanescu et al., 1998; Kato, 
2001; Linnane et al., 1989) In this argument, some authors reported an increased mtDNA- copy 
number in peripheral cells and plasma in depressed (Cai et al., 2015; Nicod et al., 2016) and 
suicidal (Lindqvist et al., 2016) subjects. Finally, several mitochondrial encephalomyopathies are 
characterized by a high prevalence of bipolar disorder and depression.(Kato, 2001) Taken together, 
these findings suggest that mitochondrial dysfunction may be associated with mood disorders, 
including depression.  
 
Even if several experimental and pre-clinical pieces of research report that mitochondrial 
dysfunction is plausible in the development of depression  (e.g. depressed people use less ATP in 
some brain regions) (Gardner et al., 2003; Karabatsiakis et al., 2014), only two studies have 
investigated an association between mitochondrial haplotypes and the presence of depression in 
human being not affected by mitochondrial myopathies.(Rollins et al., 2009; Zhang et al., 2016) 
Although these studies reported a significant association between mitochondrial haplotypes and 
mental illness, they were limited in sample size suggesting that further research is needed. 
 
Given this background, we aimed to investigate whether any mitochondrial haplogroup carried a 
significant higher risk of depressive symptoms in a large cohort of North American people included 
in the Osteoarthritis Initiative.     
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METHODS 
Data source and subjects 
All participants in this cross-sectional study were recruited as part of the ongoing, publicly and 
privately funded, multicenter Osteoarthritis Initiative (OAI study) (http://www.oai.ucsf.edu/). The 
specific dataset used was the OAI baseline data (November 2008) (V00). The OAI recruited 
participants with/at high risk of knee osteoarthritis (e.g. obese, with familiarity for OA) from four 
clinical sites in the US (Baltimore, MD; Pittsburgh, PA; Pawtucket, RI; and Columbus, OH) 
between February 2004 and May 2006. For this study, specific exclusion criteria are: pregnancy, 
presence of active rheumatoid arthritis, bilateral total knee replacement, unable to undergo knee 
magnetic resonance or to give a blood sample, any co-morbidity precluding the participation to the 
study and unwilling to sign the informed consent.    
All participants provided written informed consent. The OAI study protocol was approved by the 
institutional review board of the OAI Coordinating Center, University of California at San 
Francisco. 
 
Exposure 
The haplogroup assignment was performed by a previously published method (Rego-Perez et al., 
2008), which consisted in a combination of sequencing and PCR-RFLP techniques. The sequencing 
technique consisted in the multiplex assignment of the main 6 SNPs that contribute to the 
generation of the most prevalent Caucasian haplogroups(Torroni et al., 1996) (H, V, super HV, U, 
K, T, J) following the single base extension (SBE) assay. All the mitochondrial haplogroups have 
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been named following this nomenclature in agreement with those suggested by the OAI 
(http://www.oai.ucsf.edu/): H, U, K, J, T, V, SuperHV, I, W, X or Others. 
 
 
 
Outcome - depressive symptoms  
The presence of depressive symptoms was derived from the 20-item Center for Epidemiologic 
Studies-Depression (CES-D) instrument.(Radloff, 1977) The range of possible values for this scores 
is 0 to 60, where higher scores indicate more depressive symptoms.(Radloff, 1977) A cut-off of 16 
is commonly used for the diagnosis of depressive symptoms. (Radloff, 1977)  
 
Covariates 
A number of variables were identified from the OAI dataset to explore the relationship between 
mitochondrial haplogroups and depression. These included: (1) physical activity evaluated through 
the Physical Activity Scale for the Elderly (PASE) (Washburn et al., 1999). The PASE is validated 
in older populations, covers 12 different activities, such as walking, sports, and housework, and is 
scored from 0 to 400 and more; (2) race was defined as “white” vs. “others”; (3) smoking habits as 
“previous/current” vs. never; (4) educational level was categorized as “degree” vs. others; (5) yearly 
income as < vs. > 50,000 $ or missing data; (6) co-morbidities assessed through the modified 
Charlson comorbidity score, with higher scores indicating an increased severity of conditions(Katz 
et al., 1996); (7) body mass index (BMI), as recorded by a trained nurse.  
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Statistical analyses 
For continuous variables, normal distributions were tested using the Kolmogorov-Smirnov test. The 
data are shown as means and standard deviations (SD) for quantitative measures, and percentages 
for all discrete variables by presence of depression. For continuous variables, Student’s T test was 
used, whilst chi-square test was applied for discrete variables. Levene’s test was used to test the 
homoscedasticity of variances and, if its assumption was violated, then Welch’s ANOVA was used.  
 
The strength of the association of mitochondrial haplogroups and depressive symptoms was 
assessed through a logistic regression analysis. Factors significantly associated with depression 
(taking a p-value<0.05 as statistically significant) were included. Multi-collinearity among 
covariates was assessed through variance inflation factor, taking a cut-off of 2 as a reason of 
exclusion, but no variable was excluded due to this reason. The basic model was not adjusted for 
any confounders, while the fully adjusted model included baseline values of: age, BMI, PASE 
score, Charlson comorbidity index as continuous variables, and gender, education, smoking habits, 
yearly income as categorical variables. Data of logistic regression analysis were reported as odds 
ratios (ORs) with 95% confidence intervals (CIs).  
 
In a secondary analysis, we used controls (matched for age and sex) to depressed participants in 
order to attenuate the presence of any selection bias.(Pearce, 2016)  
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All analyses were performed using the SPSS 17.0 for Windows (SPSS Inc., Chicago, Illinois). All 
statistical tests were two-tailed and statistical significance was assumed for a p-value <0.05.  
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RESULTS 
Study participants 
At baseline, among 4,796 potentially eligible individuals, 1,047 subjects did not have a 
mitochondrial DNA assessment, 126 did not have this assessment for technical problems and 22 did 
not have information regarding CES-D. Thus, 3,601 participants were enrolled in the current study. 
Compared to those included in this analysis, the 1,195 people not enrolled were  not significantly 
differences in terms of age and gender, but there was a higher presence of non-Caucasian ethnicities 
(chi-square test, p<0.0001) (details not shown).  
 
Baseline analyses  
The 3,601 participants included aged a mean of 61.7±9.3 (range: 45-79) years, with a slight higher 
prevalence of women (=55.9%).  All participants were Caucasians.  
Participants were divided into those with depressive symptoms (n=285, 7.9% of the sample) and 
without (n=3,316).  The baseline characteristics of both groups are summarized in Table 1. Briefly, 
people with depressive symptoms were significantly older, more likely to be females, and obese 
compared to the non-depressed group. People with depressive symptoms were more frequently 
smokers, with a lower educational level, poorer and with more comorbidities than those with no 
depressive symptoms (Table 1).  
 
Association between mitochondrial haplogroups and depression 
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As reported in Figure 1, no significant differences emerged regarding in the prevalence of 
mitochondrial haplogroups (chi-square test=0.53). For example, the most frequent haplogroup (i.e. 
H) had the same prevalence among the depressed and no depressed (42.5% in both groups).  
 
Using a logistic regression analysis, adjusted for eight potential confounders, with those having the 
haplogroup H as the reference, no significant mitochondrial haplogroup was associated with a 
prevalent depressive symptoms. The OR ranged from 0.50 (95%CI: 0.18-1.43) of other haplogroup 
to 1.74 (95%CI: 0.75-4.07) of haplogroup W (Table 2).  
 
In a secondary analysis, we explored whether using controls matched for age and sex, influenced 
our results, but the association between mitochondrial haplogroups and depressive symptoms 
remained not significant (Table 2).   
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DISCUSSION 
In this large cross-sectional paper, we found there was no significant association between 
mitochondrial haplotypes and depressive symptoms. Our findings remained unaltered after 
adjusting for potential confounders or using controls matched for sex and age.  Thus, our data 
suggest that mitochondria haplogroups may not be related to depressive symptoms. 
 
The interest of mitochondrial haplotypes in the development of psychiatric diseases is rapidly 
increasing. Several studies have reported that mitochondrial haplotypes are associated with the 
presence of some psychiatric conditions, particularly schizophrenia and bipolar disorder.(Clay et al., 
2011; Rajasekaran et al., 2015) The mechanisms linking mitochondrial haplogroups and related 
dysfunction and these conditions may be attributed to altered oxidative/nitrosative stress responses 
which could activate the immunoinflammatory pathways (Bano et al., 2017; Soysal et al.; Soysal et 
al., 2016) and subsequently lead to neuroprogressive changes, typical of bipolar disorder and 
schizophrenia. (Clay et al., 2011; Rajasekaran et al., 2015) Since the same mechanisms are relevant 
for the development of depression, some researchers have tried to disentangle if any association 
exists between mitochondrial haplogroups and depressive mood.  These studies, however, are very 
limited and included few participants. Initially Suomalainen et al. reported in a family affected by a 
chronic progressive ophthalmoplegia that the presence of depression was very common. 
(Suomalainen et al., 1992) These authors interpreted this finding as a possible sign of mitochondrial 
encephalopathy. Similarly, Suzuki and collaborators investigated 15 people affected by a form of 
mitochondrial diabetes founding that four of them were affected by mood disorders. (Suzuki et al., 
1997) More recently, Rollins et al. showed that, in a peculiar subgroup of patients with 
schizophrenia, the rate of synonymous base pair substitutions in the coding regions of the mtDNA 
genome was significantly higher compared to controls. (Rollins et al., 2009). However the same 
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results were not confirmed in patients with depression compared with controls. These findings 
highlight the concept of a higher mtDNA instability in some mental disorders.  Finally, in 2016, 
Zhang et al., reported in 744 Chinese subjects with major depression matched with 767 Chinese 
healthy controls that the T-C haplotype was significantly associated with depression.(Zhang et al., 
2016) Contrary to results reported by Zhang et al, we did not find any significant association 
between mitochondrial haplogroups and depressive symptoms in our study. Several hypotheses 
could explain our findings. First, the studies cited before (except the last two) were made among 
populations affected by mitochondrial diseases and without a control group. Therefore, it is difficult 
to say whether a particular mitochondrial haplogroup is associated or not with depression. Second, 
since our knowledge regarding the possible effect of mitochondrial haplotypes on depression 
derives from the reported similarities with other psychiatric diseases and from some indirect 
findings (such as people with depression  have reduced blood flow and metabolism in the prefrontal 
cortex compared to healthy controls)(Videbech, 2000), thus it is possible that mitochondrial 
haplotypes do not play a role in the development of this disease. It is noteworthy, for example, that 
Stine et al. in postmortem samples found no significant alterations in mtDNA in nine depressed 
people who completed suicide compared to controls.(Stine et al., 1993) However our study suggests 
further studies are required to disentangle the potential relationship between mitochondria 
haplogroups and depression. Moreover, Zhang et al compared patients with a full diagnosis of 
MDD with healthy controls, thus including people with more pronounced depressive illness than 
ours which included people with depressive symptoms.(Zhang et al., 2016) Also, while we focused 
on a Caucasian population, Zhang et al focused on a Chinese sample, which might have different 
mithocondrial haplotypes’ distribution. (Zhang et al., 2016)  Furthermore, we did not account for 
stress in our analyses; since it has been suggested that stress can modify amount of mtDNA, our 
findings may have been biased by neglecting stress as confounding factor. Finally, it may be that 
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there were too few participants within each mitochondria haplogroups and thus some of our 
analyses were underpowered.   
 
 
A special consideration should also account for the close relation between mithocondrial 
functioning and ageing, in elderly population. Ageing is per sè associated with a weakened 
mitochondrial efficiency(Chistiakov et al., 2014), and mitochondrial age-related impairment may 
also play a role in depression onset(Harper et al., 2016), beyond haplotypes’ distribution. 
 
Limitations 
The findings of our paper should be interpreted within its limitations. First, the diagnosis of 
depressive symptoms was made only using the CES-D that, however, includes many symptoms 
defined by the (DSM-V) for a major depressive episode and therefore is somewhat 
justifiable(Veronese et al., 2016). Second, we did not assess the role of medications used for 
depression and this could introduce an important bias. Third, the number of people in some 
haplogroups was limited. Fourth, the medical diseases in the OAI are self-reported, and this could 
introduce another potential bias. Fifth, data was only available of mitochondrial haplogroups among 
Caucasians and the results do not extend beyond this ethnicity. Sixth, the OAI did not contain 
detailed information regarding other psychiatric diseases that seem to be associated with 
mitochondrial haplogroups and this could affect our results.  Finally, the OAI included only people 
with or at high risk of knee osteoarthritis and so it could be not fully representative of the general 
population.   
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In conclusion, in this large cohort study we did not find a relationship between any  mitochondrial 
haplogroups with depressive symptoms. Further research with different diagnostic criteria for 
depression and with a longitudinal design are needed to disentangle if any mitochondrial haplotype 
is associated with depression.  
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Figure 1. Prevalence of depressive symptoms by mitochondrial haplogroups.  
The prevalence of each haplogroup is represented as percentage in people with depressive 
symptoms or not.  
 
Table 1. Baseline characteristics by depression status.  
Variable 
Depressive 
symptoms  
(n=285) 
No depressive 
symptoms 
(n=3316) 
p-value 
Age (years) 61.9 (9.3) 59.3 (9.3) <0.0001 
Females (%) 63.2 55.3 0.001 
BMI (Kg/m
2
) 29.1 (5.5) 28.0 (4.5) <0.0001 
White race (%) All whites 
PASE (points) 156.5 (81.1) 164.1 (80.0) 0.13 
Smoking (%) 55.6 45.5 0.001 
Degree (%) 24.6 34.3 0.001 
Yearly income (<50,000 $) 46.5 68.7 <0.0001 
Charlson co-morbidity score 0.5 (0.8) 0.3 (0.8) <0.0001 
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Notes: 
Numbers are mean values (and standard deviations) or percentages, as appropriate. 
Abbreviations: BMI: body mass index; PASE:  physical activity scale for the elderly; CES-D:  
Center for Epidemiological Studies Depression.  
 
 
 
 
 
 
 
 
 
 
Table 2. Association between mitochondrial haplogroups and Depressive symptoms . 
 All cohort Matched (for age and sex) 
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Unadjusted 
OR 
(95%CI) 
P value 
Fully-
adjusted 
OR
*
 
(95%CI) 
P value 
Unadjusted 
OR 
(95%CI) 
P value 
Fully-
adjusted 
OR
*
 
(95%CI) 
P value 
H 1 [reference] 1 [reference] 1 [reference] 1 [reference] 
I 
0.77 (0.23-
2.50) 
0.66 
0.57 
(0.17-
1.91) 
0.36 
0.51 (0.15-
1.74) 
0.29 
0.37 
(0.11-
1.28) 
0.12 
J 
1.05 (0.67-
1.64) 
0.83 
0.99 
(0.63-
1.56) 
0.97 
1.00 (0.62-
1.62) 
0.99 
0.93 
(0.56-
1.52) 
0.76 
K 
1.21 (0.77-
1.91) 
0.41 
1.32 
(0.83-
2.11) 
0.24 
1.30 (0.79-
2.13) 
0.31 
1.36 
(0.81-
2.28) 
0.25 
Others 
0.61 (0.22-
1.70) 
0.35 
0.50 
(0.18-
1.43) 
0.20 
0.72 (0.24-
2.12) 
0.55 
0.45 
(0.14-
1.43) 
0.18 
SuperHV 
1.39 (0.72-
2.67) 
0.33 
1.22 
(0.63-
2.38) 
0.56 
1.08 (0.54-
2.18) 
0.82 
1.07 
(0.52-
2.22) 
0.85 
T 
0.99 (0.65-
1.51) 
0.97 
1.02 
(0.66-
1.57) 
0.94 
0.95 (0.61-
1.50) 
0.83 
0.94 
(0.58-
1.50) 
0.78 
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 All cohort Matched (for age and sex) 
  
Unadjusted 
OR 
(95%CI) 
P value 
Fully-
adjusted 
OR
*
 
(95%CI) 
P value 
Unadjusted 
OR 
(95%CI) 
P value 
Fully-
adjusted 
OR
*
 
(95%CI) 
P value 
U 
0.76 (0.52-
1.11) 
0.16 
0.78 
(0.53-
1.14) 
0.20 
0.84 (0.56-
1.27) 
0.41 
0.82 
(0.54-
1.50) 
0.37 
V 
0.89 (0.42-
1.88) 
0.89 
0.83 
(0.39-
1.79) 
0.64 
0.66 (0.30-
1.43) 
0.29 
0.56 
(0.25-
1.27) 
0.17 
W 
1.91 (0.84-
4.35) 
0.12 
1.74 
(0.75-
4.07) 
0.20 
2.12 (0.83-
5.44) 
0.12 
2.17 
(0.80-
5.91) 
0.13 
X 
1.15 (0.40-
3.26) 
0.80 
1.07 
(0.36-
3.15) 
0.91 
1.05 (0.34-
3.23) 
0.93 
1.00 
(0.32-
3.21) 
0.99 
Notes: 
All the data are presented as odds ratios (ORs) with their 95% confidence intervals. 
*
Fully-adjusted model included as covariates: age (as continuous); sex; body mass index (as 
continuous); education (degree vs. others); smoking habits (current and previous vs. others); yearly 
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income (categorized as > or < 50,000$ and missing data); Physical Activity Scale for Elderly score 
(as continuous); Charlson co-morbidity index.  
Abbreviations:  CI: confidence intervals; OR: odds ratio. 
 
 
Highlights 
 Limited data is available regarding mitochondrial haplogroups and depression.  
 In our study, no association was found between mitochondrial haplogroups and depression.  
 Future longitudinal studies are needed.  
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